Practical Neurology

04/25/2025

The U.S. Food and Drug Administration granted Fast Track Designation to an investigational -targeting therapy for disease: BIIB080 (Biogen
https://ow.ly/c2Ze50VHYOu

Alzheimer's Association American Academy of Neurology (AAN) Alzheimer's Drug Discovery Foundation

The Food and Drug Administration (FDA) has granted Fast Track Designation to BIIB080 (Biogen, Cambridge, MA), an investigational antisense oligonucleotide…

04/23/2025

New Podcast Alert! Mastering : Melody Barthelemy describes how she balances migraine with a thriving career. She is joined by Dr. Dawn Buse, who discusses research in the field of .

Listen today: https://ow.ly/H4zw50VFM7F

American Headache Society® Albert Einstein College of Medicine

04/23/2025

In people with , freedom during pregnancy was a strong predictor of postpartum seizure freedom. An analysis of the MONEAD study was presented at 2025.

https://ow.ly/7XUv50VFMCZ

American Academy of Neurology (AAN) American Epilepsy Society Epilepsy Foundation of America

For people with epilepsy of childbearing potential (PWECP) seizure freedom during pregnancy was shown to be a strong predictor of seizure freedom in the p…

04/22/2025

In diseases, patient-reported outcomes provide insight into function and quality of life. Drs Kelly, Nawaz, and Gwathmey discuss in our new issue.
https://ow.ly/prPN50VFGkX

VCU Health Virginia Commonwealth University Muscular Dystrophy Association The ALS Association

Information gleaned from patient-reported outcome measures provides valuable insights into the effects of neuromuscular disorders.

04/18/2025

Studies presented at 2025 demonstrate how reweighting ’s assessment scales like MDS-UPDRS may improve sensitivity and efficiency.
https://ow.ly/ChVy50VE8zs

Biohaven Johns Hopkins Medicine American Academy of Neurology (AAN) Parkinson's Foundation International Parkinson and Movement Disorder Society

Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and resp…

04/17/2025

( ) treatment initiated 4.5-24 hours after posterior circulation stroke was associated with improved function. Results of the EXPECTS trial published in The New England Journal of Medicine.
https://ow.ly/MMal50VBR7y

American Academy of Neurology (AAN) American Heart Association American Stroke Association Stroke AHA/ ASA

Results of the Chinese, phase 3 EXPECTS clinical trial (NCT0549476) suggest that Activase treatment (alteplase; Genentech, South San Francisco, CA) may be…

04/16/2025

disease assessment using functional & clinical measurement is the topic of our April issue, curated by Medical Editors Dr Sadjadi & Dr Cashman from Harvard Medicine.

Our new issue is now live, read it today: https://ow.ly/g3Qv50VBWlb
Harvard Medical School Massachusetts General Hospital American Academy of Neurology (AAN) American College of Physicians (ACP) Muscular Dystrophy Association

04/16/2025

, a novel mAb therapy, was associated w/ significant reductions in amyloid levels for people with mild-to-moderate ’s. Results presented at .

https://ow.ly/spau50VBGNs

Alzheimer's Association Roche American Academy of Neurology (AAN) AD/PD - Advances in Science & Therapy

Treatment with trontinemab (Roche, Indianapolis, IN), an investigational monoclonal antibody (mAb) therapy, was shown to be safe and effective in reducing…

04/16/2025

Hytrulo now approved as a prefilled syringe for self-administration for adults with and AChR+ .
https://ow.ly/8sFK50VB2SZ

ArgenX American Academy of Neurology (AAN) Muscular Dystrophy Association GBS-CIDP Foundation International Myasthenia Gravis Foundation of America, Inc.

04/15/2025

Cover art for our March issue on care features the work of Mary Amundson. Mary paints with her toes as a participant of an arts program administered by the The ALS Association.
https://ow.ly/EXTc50VxPZr
American Academy of Neurology (AAN) American Academy of Hospice and Palliative Medicine (AAHPM) Palliative Medicine International Association for Hospice and Palliative Care

04/11/2025

A wearable wristband ( ) using transcutaneous peripheral nerve stimulation significantly improves outcomes in people with essential tremor, new study shows.
https://ow.ly/FhU650VxBwR

American Academy of Neurology (AAN)

The Felix NeuroAI Wristband (Fasikl, Bloomington, MN), a transcutaneous peripheral nerve stimulation (TPNS) device worn on the wrist, significantly improv…

04/10/2025

New results from the -HD trial show may benefit individuals with disease who are not taking antidopaminergic meds (ADMs), supporting its potential as a targeted therapy.
https://ow.ly/3MXm50VxBgS

American Academy of Neurology (AAN)

New data presented at the American Academy of Neurology (AAN) 2025 Annual Meeting suggest that treatment with pridopidine (Prilenia Therapeutics; Waltham,…

04/10/2025

🧬 New data presented at AAN 2025 highlights a novel CD40 ligand inhibitor as a potential treatment for relapsing MS. Early results suggest promising efficacy and safety.
https://ow.ly/OSwN50VxzKY

Sanofi American Academy of Neurology (AAN)

Results from an open-label extension (OLE) of a phase 2 clinical trial (NCT04879628) for frexalimab (Sanofi; Bridgewater, NJ), an investigational CD40 lig…

04/10/2025

🏅 The American Academy of Neurology (AAN) 2025 Annual Meeting honored this year’s award recipients, Janis M. Miyasaki and Merit E. Cudkowciz, for their outstanding contributions to neurology in research, education, advocacy, and leadership.
https://ow.ly/LtV050VxA4Q

The American Academy of Neurology (AAN) recognized several individuals for their achievements, research contributions, service, and commitment to the fiel…

04/09/2025

⚠️ Children & teens with severe epilepsy and sleep apnea face a substantially higher risk of mortality, new research shows. Findings highlight the urgent need for early diagnosis and intervention.
https://ow.ly/2Sqv50VxOUo

American Academy of Neurology (AAN)

Study results presented at the American Academy of Neurology (AAN) 2025 Annual Meeting demonstrate that central sleep apnea (CSA) and other sleep apnea, i…

04/09/2025

📊 New 6-year data demonstrates offers sustained efficacy and safety in treating individuals with early, non–highly active MS. Long-term results support its role in early intervention.
https://ow.ly/VZ6R50Vx427

Novartis

Six-year open-label extension (OLE) results from the ALITHIOS clinical trial (NCT03650114) demonstrated that treatment with Kesimpta (ofatumumab; Novartis…

04/09/2025

New study compares vs for relapsing MS. Results suggest tolebrutinib may offer improved outcomes with fewer relapses and enhanced efficacy.
https://ow.ly/IxeV50VwPnz

Sanofi

Analysis of results from two clinical trials presented at the American Academy of Neurology (AAN) 2025 Annual Meeting revealed no significant difference i…

04/09/2025

🧠 Type 1 Breakthrough:
A new study finds that norepinephrine reuptake inhibition (NRI) therapy significantly reduces cataplexy attacks in individuals with narcolepsy type 1.
https://ow.ly/XK4X50VwP7v

Axsome

Treatment with AXS-12 (reboxetine; Axsome, New York, NY), a highly selective norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator, was …